Press Releases August 24, 2026 09:00 AM

Starling Oncology to Participate in Wells Fargo Healthcare Conference

Starling Oncology executives to present at Wells Fargo Healthcare Conference

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
STLN

Starling Oncology announced that its CEO Daniel Virnich and CFO Rob Carter will participate in the Wells Fargo Healthcare Conference on September 8, 2026, including a fireside chat. The presentation will be webcast on the company's investor relations website.

Starling Oncology to Participate in Wells Fargo Healthcare Conference
STLN
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Starling Oncology is one of the largest value-based community oncology groups in the U.S., serving approximately 2.1 million patients.
  • The company has a network of over 400 clinicians and 100 clinic locations across five states.
  • Participation in the Wells Fargo Healthcare Conference is an opportunity to present business updates and strategic vision to investors and analysts.

CERRITOS, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Starling Oncology™, Inc. (NASDAQ: STLN), (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today announced that Dr. Daniel Virnich, Chief Executive Officer, and Rob Carter, Chief Financial Officer, will participate in the Wells Fargo Healthcare Conference, being held in Boston on Tuesday, September 8, 2026, including a fireside chat from 4:30–5:05 p.m. ET.

A webcast link of the presentation will be accessible through the Investor Relations section of the Company’s website at https://investors.starlingoncology.com/.

About Starling Oncology, Inc.

Founded in 2007, Starling Oncology, Inc. (Nasdaq: STLN) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. Formerly known as The Oncology Institute, Starling Oncology offers cutting-edge, evidence-based cancer care to a population of approximately 2.1 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 400 employed and network clinicians and over 100 clinics and network locations of care across five states and growing, Starling Oncology is coordinating cancer care for the better. For more information visit www.starlingoncology.com. Please follow us on LinkedIn, X (formerly Twitter), or Bluesky.

Contacts

Media
ICR Healthcare
[email protected] 

Investors
ICR Healthcare
[email protected] 


Risks

  • Market reaction might be muted as the announcement primarily concerns a scheduled presentation rather than new clinical or financial data.
  • Starling Oncology operates in the competitive and highly regulated healthcare sector, where reimbursement and regulatory changes could impact future performance.
  • Broad economic and healthcare market conditions may affect investor sentiment and valuation despite the presentation.

More from Press Releases

Inter&Co Delivers Record 3Q26 Net Income of US$76.1 Million, With Strong Growth, Higher Margin and Better Efficiency Nov 12, 2026 Super League to Report Third Quarter 2026 Financial Results on Monday, November 16, 2026 Nov 12, 2026 UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights Nov 4, 2026 BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules Nov 4, 2026 Jasper Therapeutics Announces 1-for-30 Reverse Stock Split Nov 4, 2026